Identifying gaps in the treatment of hepatitis C in patients co-infected with HIV in Edmonton, Alberta.

[1]  Richard D Moore,et al.  Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum , 2019, Open forum infectious diseases.

[2]  Z. Butt,et al.  The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[3]  C. Coffin,et al.  Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada , 2019, Canadian Journal of Public Health.

[4]  M. Mugavero,et al.  Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. , 2018, Infectious disease clinics of North America.

[5]  M. Hellard,et al.  Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era , 2018, Journal of the International AIDS Society.

[6]  J. V. D. van der Meer,et al.  Spontaneous Clearance of Hepatitis C Virus Infection Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men , 2017, Open forum infectious diseases.

[7]  Z. Butt,et al.  The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) , 2016, EBioMedicine.

[8]  Lisa P. Barrett,et al.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[9]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[10]  M. Gill,et al.  Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[11]  D. Dieterich,et al.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[12]  E. Moodie,et al.  Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study , 2015, HIV clinical trials.

[13]  Terry Lee,et al.  Rate, delay and predictors of hepatitis C treatment in British Columbia. , 2015, Canadian journal of gastroenterology & hepatology.

[14]  T. Pilot‐Matias,et al.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.

[15]  J. Rockstroh,et al.  Managing HIV/hepatitis C co-infection in the era of direct acting antivirals , 2013, BMC Medicine.

[16]  T. Hoffmann,et al.  Cost effectiveness of patient education for the prevention of falls in hospital: economic evaluation from a randomized controlled trial , 2013, BMC Medicine.

[17]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[18]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.